Jonathan Young - 01 Nov 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Issuer symbol
AKRO
Transactions as of
01 Nov 2024
Net transactions value
-$742,551
Form type
4
Filing time
05 Nov 2024, 09:04:36 UTC
Previous filing
16 Oct 2024
Next filing
04 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $858,700 +40,716 +18% $21.09 267,002 01 Nov 2024 Direct F1
transaction AKRO Common Stock Sale $1,092,109 -34,943 -13% $31.25 232,059 01 Nov 2024 Direct F1, F3
transaction AKRO Common Stock Sale $499,525 -15,481 -6.7% $32.27 216,578 01 Nov 2024 Direct F1, F4
transaction AKRO Common Stock Sale $9,618 -292 -0.13% $32.94 216,286 01 Nov 2024 Direct F1, F5
holding AKRO Common Stock 20,000 01 Nov 2024 By EA Irrevocable Trust F2
holding AKRO Common Stock 20,000 01 Nov 2024 By CM Irrevocable Trust F2
holding AKRO Common Stock 20,000 01 Nov 2024 By JL Irrevocable Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -40,716 -100% $0.000000 0 01 Nov 2024 Common Stock 0 $21.09 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2024, previously adopted by the Reporting Person.
F2 These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.92 to $31.91, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 3.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.92 to $32.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 3.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.93 to $32.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 3.
F6 The options are vested and currently exercisable.